Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ
- 11 September 2021
- journal article
- research article
- Published by Elsevier BV in Bioorganic Chemistry
- Vol. 116, 105342
- https://doi.org/10.1016/j.bioorg.2021.105342
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LQ20B020001, LY20B020003)
This publication has 37 references indexed in Scilit:
- Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agentsJournal of Saudi Chemical Society, 2016
- PPARs at the crossroads of lipid signaling and inflammationTrends in Endocrinology & Metabolism, 2012
- Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial AgonistsPLOS ONE, 2012
- Revisiting Diabetes 2000: Challenges in Establishing Nationwide Diabetic Retinopathy Prevention ProgramsAmerican Journal of Ophthalmology, 2011
- Partial Agonists Activate PPARγ Using a Helix 12 Independent MechanismStructure, 2007
- Safety issues and prospects for future generations of PPAR modulatorsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyThe New England Journal of Medicine, 2006
- The Many Faces of PPARγCell, 2005
- Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivativesBioorganic & Medicinal Chemistry, 2004
- PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancerTrends in Pharmacological Sciences, 2000